Drug General Information |
Drug ID |
D09CVV
|
Former ID |
DNC013482
|
Drug Name |
NORSTEPHALAGINE
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H17NO3
|
Canonical SMILES |
COC1=C2CCNC3C2=C(C4=CC=CC=C4C3)C5=C1OCO5
|
InChI |
1S/C18H17NO3/c1-20-16-12-6-7-19-13-8-10-4-2-3-5-11(10)15(14(12)13)17-18(16)22-9-21-17/h2-5,13,19H,6-9H2,1H3/t13-/m1/s1
|
InChIKey |
TYZKUSBTFHNPMV-CYBMUJFWSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Dopamine D1 receptor |
Target Info |
Inhibitor |
[2]
|
Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Morphine addiction
|
Alcoholismhsa04728:Dopaminergic synapse
|
Alcoholism
|
PANTHER Pathway
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
Parkinson disease
|
Dopamine receptor mediated signaling pathway
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
Reactome
|
Dopamine receptors
|
G alpha (s) signalling eventsR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signalingWP727:Monoamine Transport
|
NRF2 pathway
|
Dopaminergic Neurogenesis
|
Parkinsons Disease Pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
Neurotransmitter Clearance In The Synaptic Cleft
|
References |
REF 1 | Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. |
---|
REF 2 | J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids. |